Efficacy

Lynparza (Olaparib) for Gynaecological Cancer

Lynparza (olaparib) is a targeted therapy known as a PARP inhibitor, which has shown efficacy in the treatment of certain types of gynaecological cancers, particularly ovarian cancer. It is specifically indicated for patients with BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Clinical trials have demonstrated that Lynparza significantly extends progression-free survival compared to placebo. In patients with BRCA mutations and advanced disease who have responded to first-line platinum-based chemotherapy, Lynparza has been shown to reduce the risk of disease progression or death by up to 70%.

The efficacy of Lynparza is also evidenced in the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Patients with HRD-positive status, including those with a BRCA mutation, derive particular benefit from Lynparza, as studies have shown a substantial improvement in progression-free survival compared to placebo.

Vegzelma (Bevacizumab-adcd) for Gynaecological Cancer

Vegzelma (bevacizumab-adcd) is a biosimilar to the original biological drug bevacizumab, which is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). It is used for the treatment of various cancers, including gynaecological cancers such as cervical and ovarian cancer. In ovarian cancer, bevacizumab has been approved for use in combination with chemotherapy for the front-line treatment of advanced disease, and for the treatment of recurrent disease in patients who are platinum-sensitive or platinum-resistant. Clinical trials have shown that the addition of bevacizumab to standard chemotherapy can improve progression-free survival in these settings.

For cervical cancer, bevacizumab in combination with chemotherapy is indicated for the treatment of persistent, recurrent, or metastatic disease. Clinical studies have demonstrated that the addition of bevacizumab to chemotherapy extends overall survival in these patients. As Vegzelma is a biosimilar, it is designed to have no clinically meaningful differences in terms of safety, purity, and potency when compared to the reference product, bevacizumab, thereby offering an alternative treatment option with similar efficacy for patients with gynaecological cancers.